onc brain

All studies · 241

• New 🧠 CNS · 2026-11-07
  Manual to automated (HyperArc) VMAT SRS transition
  Paddick GI 5.42 vs 7.09 (P<.001), time in room 10.5 vs 11.4 min, RTOG CI unchanged; HyperArc 1-yr LC 90.1% across 377 mets.
• New 🧠 CNS · 2026-11-07
  Dose-adapted single-isocenter SRS for 4 to 10 brain mets (prospective)
  mOS 8.1 mo, 1-yr OS 35.7%; 22/40 outlived DS-GPA prediction (≥17 needed for non-inferiority), 1-yr local failure 5%, no G3-5 toxicity.
• New 🧠 CNS · 2026-11-07
  Interinstitutional plan quality: Elements MME vs RapidArc single-isocenter SRS
  RapidArc lowered median V12Gy 19.2 vs 23.7 cc (P<.0001) and improved conformity; MME lowered V5Gy and mean brain dose (2.57 vs 2.76 Gy).
• New 🧠 CNS · 2026-11-07
  Automated single-isocenter SRS for multiple brain mets: outcomes and margins
  1y LC 89% per pt and 94% per lesion. Residual setup error caused coverage loss (V95 <95%) in 28 targets; simulated 1 mm GTV-PTV margin restored coverage.
• New 🧠 CNS · 2026-11-07
  DCAT vs CoVMAT vs NcVMAT for single brain met
  Non-coplanar VMAT cut normal-brain V12Gy to 9.4 vs 11.6 (DCAT) vs 15.1 cm3 (coplanar VMAT) for 2-3 cm single brain mets, 20 Gy/1 fx.
• New 🌞 Skin / Melanoma · 2026-11-06
  UK practice survey of NMSC radiotherapy
  Of 63 UK respondents, most chose one of four daily schedules (18-20 Gy/1#, 35 Gy/5#, 45 Gy/10#, 55 Gy/20#). Non-standard schedules varied widely, with 24 different regimens proposed.
• New 🌞 Skin / Melanoma · 2026-11-06
  Radiotherapy for epithelial skin cancer (Locke)
  Local control 89% overall (93% untreated vs 80% recurrent) across 531 BCC/SCC lesions; dose/fx <2 Gy predicted local failure (p=0.01).
• New 🌞 Skin / Melanoma · 2026-11-06
  Hypofractionated electron beam RT for epithelial skin cancer, 434 cases
  3-yr actuarial LRF 97.5% (54 Gy/18fx) vs 96.1% (44 Gy/10fx) with electrons for BCC/SCC; no significant difference in either histology.
• New 🌞 Skin / Melanoma · 2026-11-06
  Predictors of recurrence after RT for NMSC
  Recurrence 15.8% at median 18.4 mo across 448 RT-treated NMSCs; age, size ≥2 cm, immunosuppression and photon modality independently predicted recurrence.
• New 🧠 CNS · 2026-11-06
  Volume threshold of brain metastases for Linac-based SRS
  In a GK-vs-VMAT replanning study, GK beat VMAT on plan quality for targets ≤0.4 cc, while VMAT won for targets >0.4 cc.
• New 🌰 Prostate · 2026-11-05
  ADT Class and Cardiovascular Risk (Hahn, ASCO GU 2026)
  MACE ~four per 100 person-yrs overall; ~37% numerically lower with GnRH antagonist vs agonist; 11 per 100 person-yrs with preexisting CVD.
• New 🌞 Skin / Melanoma · 2026-11-05
  RT for nasal skin SCC, Princess Margaret experience
  Local relapse-free rate 90% at 2y and 85% at 5y, CSS 96%, no RTOG G4 late toxicity in 94 pts treated with mostly orthovoltage RT.
• New 🌞 Skin / Melanoma · 2026-11-05
  Risk factors determining prognosis of cutaneous SCC (Brantsch)
  No metastases in tumours ≤2.0 mm thick; >6.0 mm metastasized in 14/90 (16%); desmoplasia drove local recurrence (HR 16.11) after margin-controlled resection.
• New 🌞 Skin / Melanoma · 2026-11-05
  Kilovoltage RT for carcinomas overlying nasal cartilage (671 lesions)
  5-yr cure rate 88.09% and 10-yr 86.51% in 671 BCC and SCC over nasal cartilage; cosmesis good or acceptable in 96.84%.
• New 🌞 Skin / Melanoma · 2026-11-05
  Facial cutaneous carcinoma HDR contact brachytherapy with customized molds
  5-yr actuarial LC 89% (100% flat surfaces, 83% nose) with Ir-192 HDR contact mold BT, 48 Gy/12 fx, for facial BCC/SCC ≤3 mm thick.
• New 🌞 Skin / Melanoma · 2026-11-05
  Hypofractionated HDR plesiotherapy in nonmelanoma skin cancer
  3y/5y DFS 95.12%/93.36% after 3 Gy/fx HDR surface brachy for 134 BCC/SCC lesions; CR 98%, recurrent lesions did worse.
• New 🌰 Prostate · 2026-11-04 ESMO Congress 2026
  Decipher and PAM50 in NRG/RTOG 9601 and 0534
  ASTRO 2026 secondary analyses: Decipher prognostic in 9601 but not formally predictive; PAM50 luminal-B predicted STADT benefit with salvage RT in 0534.
• New 🌀 GI Lower · 2026-11-04 ESMO Congress 2026
  AZUR-1
  cCR12 68% (investigator) and cCR12+pCR 76% with dostarlimab alone in dMMR/MSI-H LARC, no recurrences to date at 26.3mo median f/u.
• New 🍽️ GI Upper · 2026-11-04 ESMO Congress 2026
  SANO
  5y OS 50% vs 54%, HR 1.17 (0.77-1.77) active surveillance vs surgery after cCR to nCRT; distant mets 46% vs 29%, P<.01.
• New 🫘 Kidney · 2026-11-04 ESMO Congress 2026
  PE-PE
  mRFS 25.4 vs 11.0 mo, HR 0.47 (0.24-0.92), p=0.024, adding 1y perioperative pembrolizumab to SABR/surgery MDT in omRCC.
• New 🌰 Prostate · 2026-11-03 ESMO Congress 2026
  DASL-HiCaP
  4-yr MFS-CI 95% vs 88%, HR 0.42 (0.27-0.66), adding darolutamide to 96-wk ADT plus prostate/bed and pelvic nodal RT in very high-risk disease.
• New 🌰 Prostate · 2026-11-02
  Decipher and PAM50 in NRG/RTOG 9601 and 0534
  No effect size reported in source tweets: Decipher and PAM50 biomarker analyses for guiding hormone therapy with salvage RT, presented by MD Anderson investigators.
• New 🌀 GI Lower · 2026-11-02
  UNION
  3-yr EFS 91.3% vs 77.4%, HR 0.33 (0.15-0.71), P=0.0029: SCRT → camrelizumab + CAPOX vs long-course CRT → CAPOX in LARC.
• New 🎀 Breast · 2026-11-02
  TOP-1 (BOOG 2016-01)
  5-yr local recurrence 14.8% (95% CI 12.3-17.5) after BCS alone without RT or ET in women ≥70 with low-risk ER+ HER2- BC.
• New 🍽️ GI Upper · 2026-11-02
  AGITG MASTERPLAN
  12-mo locoregional recurrence 20.2% vs 52.0% (P=0.022) adding SBRT 40 Gy/5fx to chemo in high-risk operable, borderline, or locally advanced pancreatic cancer.
• New 🍽️ GI Upper · 2026-10-31 ESMO Congress 2026
  KEYNOTE-975
  EFS HR 0.97 (95% CI 0.77-1.23), median 15.2 vs 14.7 mo in PD-L1 CPS ≥10: no EFS gain adding concurrent pembro to dCRT in unresectable esophageal/GEJ cancer.
• New 🫁 Thoracic / Lung · 2026-10-31 ESMO Congress 2026
  SARON
  Consolidation RT added to 1L SACT: mOS 31.0 vs 28.0mo (HR 0.99, p=0.95) despite mPFS 13.9 vs 8.9mo (HR 0.64) in synchronous oligometastatic AGA-negative NSCLC.
• New 🌰 Prostate · 2026-10-28 ESMO Congress 2026
  APCCC 2026: High-risk Localised, Locally Advanced, and Biochemically Recurrent PC
  Consensus (≥75%) reached on 44 of 134 questions (32.8%); fractionation for high-risk localised PC reached no consensus despite 88% favoring some hypofractionation.
• New 👄 Head & Neck · 2026-10-26 ESMO Congress 2026
  EORTC 1420 Best-of
  12-mo MDADI adjusted difference +3.9 points (90%CI -2.7 to +10.5; p=0.326), TOS vs DO-IMRT; no swallowing difference, more mucosal toxicity with DO-IMRT.
• New 🌞 Skin / Melanoma · 2026-10-25
  HDR brachytherapy with custom-made surface molds for facial skin carcinomas
  5y actuarial LC 98% overall (99% primary, 87% recurrent) in 136 facial BCC/SCC treated with HDR Ir-192 surface molds, no severe late complications.
• New 🌞 Skin / Melanoma · 2026-10-25
  Fractionated HDR brachytherapy moulds for carcinoma of the pinna
  13 pts with superficial pinna carcinoma treated with HDR moulds, 45 Gy/8 fx: complete resolution in all, no recurrences at minimum 18 mo f/u.
• New 🌞 Skin / Melanoma · 2026-10-25
  Skin surface brachytherapy practice-pattern survey
  16 ABS respondents: gross-disease margin 3-15mm (median 5mm), doses 30 Gy/5fx to 64 Gy/32fx (EQD2 40-65 Gy), no consensus on dosimetric constraints.
• New 🌞 Skin / Melanoma · 2026-10-25
  CT-based flap brachytherapy for facial non-melanoma skin cancers
  1-yr KM local control 92% after HDR flap brachy 40 Gy/8 fx twice weekly for T1 facial BCC/SCC; no chronic G≥3 toxicity.
• New 🌞 Skin / Melanoma · 2026-10-25
  Surface mould brachytherapy for skin cancers: British Columbia Cancer experience
  2-yr LC 84.9%, CR 96.8%, no G3+ toxicity with CT-planned Ir-192 HDR surface mould in 65 mostly head-and-neck skin lesions.
• New 🎯 Oligometastatic / Mets · 2026-10-25
  SARON
  mOS 31.0 vs 28.0 mo, HR 0.99 (0.63-1.55), adding consolidation RT to SACT in synchronous oligometastatic driver-negative NSCLC; PFS improved, magnitude not given.
• New 💧 Bladder · 2026-10-25
  Bladder preservation after neoadjuvant/perioperative therapy in MIBC (reTURBT cohort)
  ypT0Nx at reTURBT after neoadjuvant therapy: 24-mo EFS 87.6%, OS 96.7% in MIBC pts declining RC (n=54); non-pCR pts fared far worse.
• New 🚀 Practice-changing 🫁 Thoracic / Lung · 2026-10-24 ESMO Congress 2026
  DeLLphi-305
  mOS 21.1 vs 12.7 mo, HR 0.42 (0.32-0.54), adding tarlatamab to durvalumab 1L maintenance in ES-SCLC after chemo-IO induction.
• New 🫁 Thoracic / Lung · 2026-10-24 ESMO Congress 2026
  SBRT for Ultra-Central Lung Tumors Meta-Analysis
  Pooled 1-yr LC 92% and 2-yr LC 89% after ultra-central lung SBRT; G5 toxicity 4%, mostly hemoptysis, across 27 mostly retrospective studies.
• New 🌰 Prostate · 2026-10-24 ESMO Congress 2026
  PEACE-1
  mOS 6.2 vs 4.4y (HR 0.68) adding abiraterone to ADT+docetaxel at 8y FU, n=710; no treatment-by-volume interaction (P=0.5552).
• New 🌰 Prostate · 2026-10-24 ESMO Congress 2026
  STAMPEDE, ENZARAD, PROTEUS and DASL in context
  ESMO26 round-up of four intensification trials. STAMPEDE Decipher update suggests differential abiraterone benefit in cN0 disease (interaction P=.01).
• New 🌰 Prostate · 2026-10-24 ESMO Congress 2026
  DASL-HiCaP
  4-yr MFS-CI 95% vs 88%, HR 0.42, adding darolutamide to prostate/bed + pelvic LN RT and 96 wk ADT in very high-risk prostate cancer.
• New 🌰 Prostate · 2026-10-24 ESMO Congress 2026
  PROTEUS Substudy
  EFS HR 0.38 (95% CI 0.26-0.55) with perioperative apalutamide + ADT around RP + PLND in HR LPC/LAPC; MFS HR 0.49, nominal p only.
• New 🌐 Lymphoma · 2026-10-24 ESMO Congress 2026
  Low-Dose Involved Field RT in Indolent Lymphomas
  4 Gy involved-field RT in recurrent indolent lymphoma: ORR 92%, CR 61%, median time to local progression 25 mo, toxicity virtually absent.
• New 🤝 Supportive / QoL · 2026-10-24 ESMO Congress 2026
  Nonspine Bone Metastases SBRT Practice Patterns
  35 Gy/5 most often chosen (29/99 responses); 40 Gy/5 acceptable to 8 or 9 of 9 experts wherever listed; every schedule BED ≤100 Gy10.
• New 🤝 Supportive / QoL · 2026-10-24 ESMO Congress 2026
  Single-Fraction SBRT vs Multifraction RT for Nonspine Bone Metastases
  3-mo ITT pain response 38% vs 21% (P=.05) with 12-16 Gy single-fraction SBRT vs 30 Gy/10; 2-yr local PFS 100% vs 75.6%.
• New 🌷 Gynecologic · 2026-10-23
  Postoperative endometrial cancer with electronic brachytherapy (Axxent)
  Axxent eBT vs replanned Ir-192 HDR: bladder D2cc 63.8% vs 70.1%, rectum 61.2% vs 68.4% of prescription; one G2 acute toxicity in 94 pts.
• New 🌷 Gynecologic · 2026-10-23
  PORTEC-3
  5y FFS 75.5% vs 68.6% (HR 0.71, p=0.022) with CRT over pelvic RT alone; co-primary 5y OS 81.8% vs 76.7% not met (HR 0.76, p=0.11).
• New 🌷 Gynecologic · 2026-10-23
  HDR vaginal brachytherapy cylinder dosimetry
  Surface SD 6% vs 18% with surface vs 0.5-cm depth prescription (2-cm cylinder). Omitting dome optimization points gave hot spots >150% and cold spots <60%.
• New 👄 Head & Neck · 2026-10-23
  Composite pathologic risk stratification, resected HPV+ oropharyngeal cancer
  Traditional pathologic risk tiers discriminate poorly in resected HPV+ OPSCC (C-index 0.58); a points-based composite reaches 0.67 and moves high-risk share from 45.1% to 6.6%.
• New 🎯 Oligometastatic / Mets · 2026-10-23
  Gomez LCT oligometastatic NSCLC (long-term results)
  mOS 41.2 vs 17.0 mo (P=.017) and mPFS 14.2 vs 4.4 mo favoring LCT over maintenance/observation in oligometastatic NSCLC after front-line therapy.
• New ♂️ Germ Cell / Other GU · 2026-10-22
  Nodal metastasis mapping in seminoma (RT fields)
  Across 145 imaging-positive nodes in 90 pts, 99% sat within a 2.5cm lateral/posterior and 2.1cm anterior arterial expansion, smaller than Classen fields.
• New ♂️ Germ Cell / Other GU · 2026-10-22
  Classen reduced-portal RT for stage IIA/B seminoma
  6-yr RFS 95.3% (IIA) and 88.9% (IIB) with para-aortic/ipsilateral high iliac RT, 30/36 Gy; 100% in-field control, no late toxicity.
• New 🌰 Prostate · 2026-10-22
  F-SHARP
  No acute G3+ toxicity and 3-yr bPFS 62.7% after dose-escalated focal salvage HDR (up to 30 Gy/1-2 fx) for intraprostatic radiorecurrence, N=62.
• New 🌰 Prostate · 2026-10-22
  Prostate SBRT intra-fraction motion and margins
  Current 6 mm/3 mm posterior PTV margins covered IFPM in 92% of fractions. BIR-guideline margins ran from 3.3 mm laterally and posteriorly to 7.0 mm inferiorly.
• New 🌰 Prostate · 2026-10-22
  RTOG 9601
  12-yr OS 76.3% vs 71.3%, HR 0.77 (0.59-0.99), adding 24mo bicalutamide 150mg to salvage RT in pN0 post-RP pts with PSA 0.2-4.0.
• New 🌰 Prostate · 2026-10-21
  NRG/RTOG 0415 late toxicity tolerance doses
  Rectal D5% (EQD2) ≤62 Gy predicted halving late ≥G2 GI toxicity from 20% to 10% after 70 Gy at 2.5 Gy/fx in low-risk prostate cancer.
• New 🌰 Prostate · 2026-10-21
  Moderate hypofractionation 70 Gy/28 fx, 10-year outcomes
  10-yr bRFS 71%, cRFS 86%, PCSM 6.8% after 70 Gy/28 fx IMRT for localized prostate cancer; late G≥3 GU 2%, GI 1%.
• New 🌰 Prostate · 2026-10-21
  Integrated clinical-genomic risk groups (Decipher + NCCN)
  10y DM 3.5%/29.4%/54.6% for clinical-genomic low/int/high vs NCCN 7.3%/9.2%/38.0%/39.5% in localized prostate cancer; 30% reclassified.
• New 🌰 Prostate · 2026-10-21
  HYPO-RT-PC
  5yr FFS 84% vs 84%, adjusted HR 1.002 (95% CI 0.758-1.325): 42.7 Gy/7 fx non-inferior to 78 Gy/39 fx in intermediate-to-high-risk prostate, no ADT.
• New 🎀 Breast · 2026-10-21
  High-risk T1-T2N0 breast, LRR without PMRT
  Crude LRR 4.7% at median 5.6y after mastectomy without PMRT in T1-T2N0 with ≥1 high-risk feature; only tumor size predicted LRR (HR 1.70).
• New 🎀 Breast · 2026-10-20
  21-gene Recurrence Score and locoregional recurrence in node-positive breast cancer (SWOG 8814 correlative)
  10-yr LRR 16.5% vs 9.7% for RS ≥18 vs <18 (P=.02) in ER/PR+ node-positive breast; widest split at 1-3 nodes after mastectomy without RT.
• New 🎀 Breast · 2026-10-20
  Locoregional recurrence after neoadjuvant chemotherapy: pooled analysis of nine trials
  5-yr LRR 4.1% with pCR vs 9.5% without (multivariate HR 3.33); TNBC non-pCR 18.5%. Surgery type not independent after NACT.
• New 🎀 Breast · 2026-10-20
  PMRT selection in T1-T2, 1-3 node-positive breast cancer
  10y KM LRR±SDR 15.9% without PMRT in pT1-T2 1-3 N+; age <45 with >25% nodes positive reached 58.0%.
• New 🎀 Breast · 2026-10-20
  CPS+EG staging and local-regional recurrence after neoadjuvant chemotherapy
  5-yr freedom from LRR by CPS+EG score spanned 71% to 99%, vs 86% to 97% by clinical or pathologic stage, in 1697 pts after NACT.
• New 🎀 Breast · 2026-10-20
  Long-term impact of regional nodal irradiation after neoadjuvant systemic therapy
  Adjusted LRR HR 0.497 and DR HR 0.731 with RNI after NAT in cN+ stage II-III breast; unadjusted 10-yr LRR 9.4% vs 8.1%, P=.62.
• New 🎀 Breast · 2026-10-19
  EBCTCG 20-year recurrence after 5 years of endocrine therapy
  After stopping endocrine therapy at 5y, distant recurrence in years 5-20 ran from 13% (T1N0) to 41% (T2N4–9), at a steady annual rate.
• New 🎀 Breast · 2026-10-19
  SAKK 23/82
  5-yr DFS 61% vs 40% with tamoxifen after excision + RT for good-risk post-mastectomy ILRR; OS unchanged (median 11.5 vs 11.2 yr, P=0.79).
• New 🎀 Breast · 2026-10-19
  Node-negative post-mastectomy LRR and prognostic factors
  10y LRR 6.0% overall in N0 post-mastectomy pts without PMRT, rising to 40.6% with 3 risk factors (size >2 cm, margin <2 mm, premenopausal, LVI).
• New 🎀 Breast · 2026-10-19
  NSABP B-15/B-16/B-18/B-22/B-25 IBTR and LRR prognosis
  After lumpectomy + WBI in node-positive pts, IBTR (HR 2.58) and other LRR (HR 5.85) predicted death; 5-yr OS 59.9% vs 24.1%.
• New 🎀 Breast · 2026-10-19
  T1-2N1 mastectomy without PMRT (MSKCC)
  10y LRR 7.0% without PMRT vs 4.0% with it (p=0.32) in T1-2N1 after mastectomy; age <40 + LVI reached 28% without PMRT.
• New 🎀 Breast · 2026-10-18
  Close or positive margin after mastectomy and chest wall irradiation
  8yr cumulative chest wall recurrence 28% age ≤50 vs 0% age >50 (p=0.04) with close/positive margin, T ≤5cm, 0-3 nodes, no PMRT.
• New 🎀 Breast · 2026-10-18
  Isolated local-regional recurrence after mastectomy: radiotherapeutic management
  5-yr freedom from chest wall re-recurrence 75% with whole-chest-wall fields vs 36% with small fields (p=0.0001) in 224 pts irradiated for isolated LRR.
• New 🎀 Breast · 2026-10-18
  Nomogram for four or more involved nodes in SLN-positive breast cancer
  AUC 0.83 in derivation and 0.81 in external validation for predicting ≥4 involved nodes after 1-3 positive SLNs, using 7 pathologic factors.
• New 🎀 Breast · 2026-10-18
  Nomogram for locoregional recurrence in T1-2N1 breast cancer (PMRT decision-making)
  High-risk nomogram tier (score >18): PMRT 5y LRR 2.2% vs 14.9%, HR 0.164; no LRR association in low or intermediate tiers.
• New 🎀 Breast · 2026-10-18
  Chest wall recurrence outcome by initial stage
  5-yr OS after isolated CWR 79.9% vs 41.9% vs 29.1% (T1-T2N0 vs T1-T2 1-3 N+ vs T3-T4/>4 N+); 1-3 N+ salvage as poor as advanced stage.
• New 🎀 Breast · 2026-10-17
  RT CHARM (Alliance A221505)
  24-mo reconstruction complications 12.3% (42.56 Gy/16 fx) vs 10.2% (50 Gy/25 fx), difference -2.1% (95% CI -6.5 to 2.2); noninferior.
• New 💧 Bladder · 2026-10-16
  AUA 2026: Consolidative local therapy after EV+pembro response (surgery vs radiation vs surveillance)
  RT-based preservation, cystectomy and surveillance each argued for cCR after neoadjuvant EV+pembro in MIBC; no randomized data compare the three options.
• New 🧠 CNS · 2026-10-04 ASTRO Annual Meeting 2026
  TRIDENT
  No OS gain starting TTFields with RT/TMZ vs at maintenance TMZ in ndGBM: mOS 17.7 vs 17.5 m, HR 0.953, p=0.52.
• New 🧠 CNS · 2026-10-04 ASTRO Annual Meeting 2026
  NRG-CC009
  Neurocognitive failure no different for SRS vs HA-WBRT + memantine in SCLC brain mets (adjusted HR 0.83, p=0.39); OS 17.4 vs 8.6 mo favoring SRS.
• New 🧠 CNS · 2026-10-04 ASTRO Annual Meeting 2026
  Alliance A071801
  1 year surgical bed control 87% vs 81% (p=0.046) favoring fSRS over single-fraction SRS after brain met resection; mOS 29 vs 20 mo.
• New 🌰 Prostate · 2026-10-04 ASTRO Annual Meeting 2026
  PACE-A (sexual function, 5-year)
  5y median EPIC-26 sexual score change -42 after prostatectomy vs -17 after SBRT (p=0.02); IIEF-5 median 5 vs 19 (p<0.001).
• New 🌰 Prostate · 2026-10-04 ASTRO Annual Meeting 2026
  NRG/RTOG 9601 (transcriptomic analysis)
  Secondary analysis, n=352, 18.2y median f/u: GC per 0.1 prognostic for PCSM, sHR 1.34 (1.17-1.54); AAT benefit by GC showed no significant interaction.
• New 🌰 Prostate · 2026-10-04 ASTRO Annual Meeting 2026
  NRG-GU003
  5-yr: G3 GU AEs 13% HYPORT (62.5 Gy/25 fx) vs 3% COPORT (66.6 Gy/37 fx), p=0.003; EPIC scores and 5-yr BF (21% vs 18%) no different.
• New 🍽️ GI Upper · 2026-10-04 ASTRO Annual Meeting 2026
  SOFT Preop
  Path node positivity 41% SBRT vs 38% chemo-RT (p = 0.754) preop in PDAC; mOS 26.04 vs 42.96 mo (p= 0.639); QOL favored SBRT.
• New 👄 Head & Neck · 2026-10-04 ASTRO Annual Meeting 2026
  NRG-HN009 (p16-negative phase II toxicity)
  T-score ratio (weekly/Q3) 1.11, p=0.77: weekly cisplatin not less toxic with 70 Gy in p16-negative locoregionally advanced SCCHN, no phase III.
• New 🚀 Practice-changing 🌐 Lymphoma · 2026-10-04 ASTRO Annual Meeting 2026
  30 Gy vs 40 Gy consolidative RT, limited-stage DLBCL
  5-yr PFS 90.5% (30 Gy) vs 87.2% (40 Gy), HR 0.87 (0.59-1.28), non-inferiority met in stage I-II DLBCL in CR after chemo.
• New 🌀 GI Lower · 2026-10-04 ASTRO Annual Meeting 2026
  TORCH-iTNT
  CR (pCR + cCR) 61.5% with SCRT 25Gy/5Fx → CAPOX + toripalimab vs 37.1% without RT in pMMR LARC; no p-value reported.
• New 🌀 GI Lower · 2026-10-04 ASTRO Annual Meeting 2026
  STELLAR II
  Overall CR 51.9% vs 26.8% (P<0.001) adding sintilimab to SCRT (5 Gy x5) + CAPOX TNT in pMMR LARC; 3-year DFS pending.
• New 🩹 Myeloma / Plasma Cell · 2026-10-04 ASTRO Annual Meeting 2026
  Ultralow-dose 4 Gy RT for myeloma bone metastases
  Pain response 59% at 4 wks (per protocol; ITT 40/70, 57%) after 4Gy to painful MM bone lesions; 24% needed a second RT course.
• New 🟡 Hepatobiliary · 2026-10-04 ASTRO Annual Meeting 2026
  NRG-GI003
  Protons did not improve OS vs photons in unresectable HCC: HR 1.30 (90% CI 0.83-2.04), futility boundary crossed at planned interim.
• New 🎀 Breast · 2026-10-04 ASTRO Annual Meeting 2026
  CHN HYPOPMRT (10-year)
  10yr LRR 12.0% (43.5 Gy/15fx) vs 10.3% (50 Gy/25fx), HR 1.19 (95% CI 0.79-1.82); G1-2 pulmonary fibrosis 19.7% vs 11.7%.
• New 🟡 Hepatobiliary · 2026-10-03
  TARE vs SBRT for HCC: decision-making talk
  Both TARE and SBRT can deliver ablative RT in HCC; phenotype should pick the modality, SBRT attractive with MVI, arterial constraints, or non-invasive preference.
• New 🌰 Prostate · 2026-10-01 ASTRO Annual Meeting 2026
  NRG/RTOG 0815 Decipher GC
  10-yr DM absolute benefit from adding STAD to dose-escalated RT: 11% in high GC vs 1% in low GC, p-interaction <0.001.
• New 🌰 Prostate · 2026-10-01 ASTRO Annual Meeting 2026
  NRG/RTOG 0534 PAM50
  5-y FFP benefit from adding ADT to post-RP salvage RT was 31% vs 10% by PAM50 Luminal B status (p-int=.01), secondary biomarker analysis.
• New 🌰 Prostate · 2026-10-01 ASTRO Annual Meeting 2026
  GETUG P05
  5-yr PSA-PFS 87.8% vs 88.8% (p=0.86): brachy boost no better than 80 Gy EBRT in intermediate-risk prostate cancer without ADT, with more late GU toxicity.
• New 🌰 Prostate · 2026-10-01 ASTRO Annual Meeting 2026
  PROSTOX Ultra (SCIMITAR, EXCALIBUR)
  Continuous AUC 0.814 (SCIMITAR) and 0.824 (EXCALIBUR) for late G2+ GU AEs after post-prostatectomy SBRT; intact-prostate 0.50 cutoff failed, 0.25 recalibrated.
• New 🌰 Prostate · 2026-10-01 ASTRO Annual Meeting 2026
  GUAM International Consensus Guideline
  48-expert modified Delphi (15 countries) sets first RT-specific GU adverse event management consensus; 76% favor moderate hypofractionation over SBRT at baseline IPSS 15–19.
• New 🌰 Prostate · 2026-10-01 ASTRO Annual Meeting 2026
  NRG/RTOG 0815
  14-y OS 53% vs 58% (HR 0.87, p=0.13) adding 6 mo STAD to dose-escalated RT in intermediate-risk prostate cancer; PSA failure HR 0.60.
• New 🌰 Prostate · 2026-10-01 ASTRO Annual Meeting 2026
  Biomarkers in Post-operative Prostate Cancer (Spratt)
  5y MFS 95% vs 82% (HR 0.27) with apalutamide + salvage RT in PAM50 luminal B, flat in non-luminal B (NRG GU006).
• New 🎯 Oligometastatic / Mets · 2026-10-01 ASTRO Annual Meeting 2026
  LUNAR vs SATURN
  Median time to progression 19.4 mo SBRT + RLT vs 21.7 mo SBRT + AAT vs 6.0 mo SBRT alone in M1 oligorecurrent PCa post-RP.
• New 🌰 Prostate · 2026-09-30 ASTRO Annual Meeting 2026
  REVELUTION (relugolix vs leuprolide + RT, PROs)
  At 12 mo, relugolix vs leuprolide with RT: IPSS 5.66 vs 9.22 (p=0.039), EPIC-CP total 12.25 vs 17.25 (p=0.02); post hoc.
• New 🌰 Prostate · 2026-09-30 ASTRO Annual Meeting 2026
  RTOG 3506 (STEEL)
  PFS HR 0.62 (80% CI 0.42-0.91, one-sided p=0.052) adding enzalutamide to SRT + 24mo ADT in high-risk post-RP BCR; BF at 2y 11% vs 19%.
• New 🌰 Prostate · 2026-09-28 ASTRO Annual Meeting 2026
  STOP: iADT ± SBRT in PSMA PET-oligometastatic HSPC/BCR
  3-yr biochemical progression 21% vs 60% (p=0.004) with SBRT added to iADT in PSMA PET+/CI-oligometastatic HSPC/BCR, n=60.
• New 🌰 Prostate · 2026-09-28 ASTRO Annual Meeting 2026
  PACE-A
  SBRT 36.25 Gy/5fx vs prostatectomy: 13 BCF events, HR 0.48 (95% CI 0.16-1.46), p=0.18; 5-yr BCF-free 94.8% vs 94.1% in localised low/intermediate-risk PCa.
• New 🧠 CNS · 2026-09-28 ASTRO Annual Meeting 2026
  ROADS
  Time-to-SBR HR 0.06 (0.01-0.46) for Cs-131 tiles vs post-op cavity SRT after brain met resection; 12-mo SBR 1.3% vs 15.4%.
• New 🫁 Thoracic / Lung · 2026-09-28 ASTRO Annual Meeting 2026
  SWOG S1827/MAVERICK
  CFFS HR 0.60 (90% CI 0.46-0.78) favoring MRI surveillance alone over PCI 25 Gy/10 fx in LS/ES-SCLC; interim OS HR 0.90.
• New 🎯 Oligometastatic / Mets · 2026-09-26
  LAVA-CRLM
  1-yr freedom from local progression 83.0% SBRT vs 77.7% MWA (HR 0.87, p=0.70); treatment-related G2+ toxicity 3% vs 25% in oligometastatic CRLM.
• New 🧠 CNS · 2026-09-25
  ROAM/EORTC-1308
  Adjuvant IMRT 60 Gy/30 fx vs observation after complete resection of WHO grade 2 atypical meningioma: DFS HR 0.51 (0.27–0.97); 5-yr DFS 79.9% vs 64.3%.
• New 🚀 Practice-changing 🎀 Breast · 2026-09-23
  BIG 3-07/TROG 07.01
  Tumour bed boost after WBI in resected non-low-risk DCIS: 5-yr freedom from LR 97.1% vs 92.7%, HR 0.47 (0.31-0.72), p<0.001.
• New 🌰 Prostate · 2026-09-22
  Testosterone Treatment in Prostate Cancer Survivors (Bhasin RCT)
  Sexual activity +0.91 daily events vs placebo (95% CI 0.56-1.26, P<.001), zero biochemical recurrences, 12wk TRT in hypogonadal men post-RP for Gleason 3+3/3+4.
• New 💧 Bladder · 2026-09-21
  ASTRO Clinical Practice Guideline: RT for Bladder Cancer
  TMT recommended (strong, high QoE) as alternative to RC for select cT2-4aN0M0 MIBC; bladder-alone 5500 cGy/20 fx or 6400-6480 cGy/32-36 fx.
• New 🧠 CNS · 2026-09-20
  Gamma Knife vs LINAC-based radiosurgery for vestibular schwannoma (retrospective review)
  Local control 98.8%; no difference in new vertigo, gait disturbance or facial palsy with GKRS (n=36) vs LINAC (n=49) SRS for vestibular schwannoma.
• New 🫁 Thoracic / Lung · 2026-09-14
  SWOG S1827/MAVERICK
  Randomized phase III, LS or ES SCLC: PCI 25 Gy/10 fx + MRI vs MRI surveillance alone; no CFFS or OS results in source tweets.
• New 👄 Head & Neck · 2026-09-09
  TORPEdO
  18% vs 7% 12-mo G-tube dependence/≥20% weight loss (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56): IMPT not superior to IMRT, locally advanced oropharyngeal SCC.
• New 🌰 Prostate · 2026-08-29
  PROTEUS
  5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.
• New 🌰 Prostate · 2026-08-27 ASTRO Annual Meeting 2025
  MARCAP Consortium
  IPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
• New 🌀 GI Lower · 2026-08-24
  STAR-TREC
  12-mo TME-free survival 78.5% vs 60.6% (HR 1.90) favouring LCCRT over SCRT for organ preservation in mrT1-T3bN0 rectal cancer ≤40 mm.
• New 🌰 Prostate · 2026-08-21
  Focal Ablation vs IMRT Toxicity (SEER-Medicare)
  GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
• New 🌰 Prostate · 2026-08-14
  NRG-GU005
  3yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.
• New 🌰 Prostate · 2026-08-13
  Testosterone recovery post-ADT discontinuation (podcast review)
  Review of two datasets: 25% of real-world pts recovered T within 12mo; 54% relugolix vs 3% leuprolide at 90d in HERO.
• New 🎀 Breast · 2026-08-13
  Moderately hypofractionated partial breast reirradiation
  40Gy/15fx PBI re-RT after second lumpectomy: 3yr LR-FS, DR-FS and OS all 86%, no grade 3+ late events (N=11).
• New 🎀 Breast · 2026-08-12
  NSABP B-35 margin-width analysis
  10yr IBTR 5.6% vs 4.0% at 1mm cutoff (abs diff 1.6%), 5.3% vs 3.8% at 2mm (abs diff 1.5%).
• New 🎀 Breast · 2026-08-12
  Cardiac Risk After Heart-Sparing Breast Radiotherapy
  Max LAD ≥12 Gy EQD2: sHR 1.81 (1.04-3.16) for cardiac events; mean heart dose ≥2 Gy null (P=.99), 2223 left-sided pts.
• New ⚠️ Safety / Regulatory · 2026-08-10
  Organs at Risk Radiation Dose Constraints: 2025 Update
  SFRO 2025 OAR dose-constraint update: normofractionated, moderate hypofractionated and ablative tables across skull base, H&N, lung, breast, oesophagus, liver.
• New 🌰 Prostate · 2026-08-10
  HERO
  90-day testosterone recovery to ≥280 ng/dL 53.9% with relugolix vs 3.2% with leuprolide after 48wk ADT.
• New 🟡 Hepatobiliary · 2026-08-08
  BEACON-HCC
  New North American HCC allocation framework; expert decisions 96.6% concordant with BEACON vs 72.4% with BCLC 2025 across 29 cases.
• New 🌰 Prostate · 2026-08-07
  PSMA PET Natural History Study in PSMA-Positive BCR
  Baseline data on first 130 pts: most BCR men with PSADT >9-12mo still have PSMA PET findings once PSA exceeds 5.
• New 🌰 Prostate · 2026-08-07
  USPCC 2026 Point-Counterpoint: PSMA PET Response Assessment in APMR
  High vs low δ-percent SUVmax carried HR 5.03 (1.17-21.65) for OS; δ-absolute SUVmax HR 9.31 (1.81-47.87).
• New 🌀 GI Lower · 2026-08-07
  STELLAR
  3yr DFS 64.5% v 62.3% (HR 0.883, NI margin 1.43, P<.001 NI): 5x5Gy then CAPOX non-inferior to 50Gy/25f CRT in LARC.
• New 🌀 GI Lower · 2026-08-07
  TNTCRT
  3-year DFS 74.8% v 66.0%, HR 0.674, for doublet CAPOX bracketing long-course chemoradiation vs conventional nCRT in high-risk LARC.
• New 🌀 GI Lower · 2026-08-01
  SIB-CRT vs Standard CRT for LARC (NCT02195141)
  9yr LC 87.1% vs 70.1% (HR 0.40, P=0.038) and OS 74.3% vs 48.9% (HR 0.43) favoring SIB dose escalation.
• New 🫘 Kidney · 2026-07-31
  IROCK RCC SABR contouring guidelines
  First international consensus on target delineation for localized RCC SABR: 16 experts, median DSC 0.85 vs consensus, >0.70 in every case.
• New 🌰 Prostate · 2026-07-31
  GÖTEBORG-1 active surveillance, 25-year follow-up
  25-yr PC-specific survival 94% (CI 91-98%) on AS, but 22-yr failure-free survival 68% and treatment-free survival 38%.
• New 🌰 Prostate · 2026-07-31
  POSEIDON
  IPD meta-analysis of 6 RCTs: adding HT to PORT did not improve OS (HR 0.87, 95% CI 0.76–1.01, p=0.06); benefit confined to pre-PORT PSA >0.5 ng/mL.
• New 💧 Bladder · 2026-07-31
  Dose-escalated RT for MIBC (retrospective)
  2y invasive local recurrence 5.5% vs 27.5% with SIB dose escalation in MIBC TMT (adjusted SHR 0.20, p=0.035); no OS, MFS or G2+ toxicity difference.
• New 🫁 Thoracic / Lung · 2026-07-31
  Proactive immune cell sparing SBRT (NCT04273893)
  Immune-sparing lung SBRT planning cut ALC loss: overall improvement 13.4% (95% CI 2.8-24.0), G3 lymphopenia 0% vs 15.4%; survival trend unpowered.
• New 🚀 Practice-changing 🎀 Breast · 2026-07-29
  DBCG Skagen Trial 1
  3yr lymphedema 8.0% (40Gy/15fx) vs 9.4% (50Gy/25fx), OR 0.84 (0.62-1.14), noninferior; no recurrence or mortality differences at 8yr.
• New 🌰 Prostate · 2026-07-26
  PACE-B
  5-yr PROMs: leak-free 64% (164/258) SBRT vs 69% (172/249) CRT, p=0.19; no domain differed significantly.
• New 🌰 Prostate · 2026-07-22
  ProtecT (cribriform morphology secondary analysis)
  Secondary analysis: cribriform-negative disease (87% of reviewed cohort) got no significant 15-yr metastasis reduction from early radical treatment vs monitoring.
• New 🌰 Prostate · 2026-07-22
  ESTRO Prostate SBRT Consensus Recommendations
  Delphi: 36.25 Gy/5 fx standard, 100% vote against elective pelvic nodal RT with prostate SBRT outside trial.
• New 🌰 Prostate · 2026-07-19
  TROG 08.03 RAVES QOL Substudy
  Severe urinary leakage 16% vs 2% at 5yr with aRT vs no RT; timing of salvage RT unrelated to QOL.
• New 🚀 Practice-changing 🌰 Prostate · 2026-07-15
  STAMPEDE abiraterone ± enzalutamide in high-risk non-metastatic prostate cancer (meta-analysis)
  MFS HR 0.53 (0.44-0.64) and OS HR 0.60 (0.48-0.73) adding 2yr abiraterone ± enzalutamide to ADT in high-risk non-metastatic prostate cancer.
• New 🫁 Thoracic / Lung · 2026-07-14
  Consolidative TRT + Atezolizumab Maintenance in ES-SCLC
  Primary EP missed: mOS 6.7 vs 13.4mo (HR 1.55, P=.34) with consolidative 30Gy/10fx; trial halted for fatal SAEs.
• New 🧠 CNS · 2026-07-13
  EANO Consensus Statement on Radiation Necrosis
  Delphi consensus: 53/57 statements reached ≥80% agreement across 20 experts; perfusion MRI + amino acid PET preferred, bevacizumab for steroid-refractory RN.
• New 🎀 Breast · 2026-07-09
  SUPREMO
  Editorial critique: chest-wall-only RT cut 10yr CW recurrence 1.1% vs 2.5% (HR 0.45) but RNI was prohibited.
• New 🌰 Prostate · 2026-07-09
  ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate Cancer
  Conference education session on SBRT for UIR prostate: 5 fractions over 1-2wks, 1-2% bothersome toxicity vs 10-30% with 45-fraction 2D era.
• New 🌰 Prostate · 2026-07-09
  HYDRA
  No PFS difference for either isodose (HR 0.92) or dose-escalated MHFRT (HR 0.94), but escalation raises late G2+ GI (OR 1.48).
• New 👄 Head & Neck · 2026-07-08
  ESTRO OCSCC Post-op CTV Delineation Guidelines
  First ESTRO guideline for post-op CTV delineation in oral cavity SCC: GTV-P pre-op + 10 mm composited with surgical defect/flap + 5 mm.
• New 🌰 Prostate · 2026-07-08
  NRG-GU005 (quality of life)
  Fewer MCID declines with SBRT at 1yr bowel (33% vs 46%, p=0.002) and sexual (34% vs 44%, p=0.026).
• New 🌰 Prostate · 2026-07-08
  10-yr SBRT Survival/Toxicity (Meier et al.)
  10-yr RFS 90% overall (94% LR, 86% IR) with 40 Gy/5 fx; grade 3 late toxicity 1.4-1.5%, no grade 4-5.
• New 🌰 Prostate · 2026-07-08
  American Radium Society AUC: Local Intraprostatic Recurrence
  Severe GU toxicity 20% after salvage RP vs 5.6% SBRT, 9.6% HDR: panel prefers biopsy-confirmed reirradiation.
• New 🚀 Practice-changing 🎀 Breast · 2026-07-07
  SUPREMO
  10yr OS 81.4% vs 81.9% (HR 1.04, 0.82-1.30, p=0.80): PMRT omission safe in intermediate-risk pN0-pN1 post-mastectomy.
• New 🌰 Prostate · 2026-07-07
  ARTO
  Adding SBRT to all met sites improved OS: median NR vs 50 mo, HR 0.55 (0.33-0.92), p=0.021 in omCRPC.
• New 🧠 CNS · 2026-07-07
  EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU
  Mature phase III: RT (50.4Gy/28fx) vs dose-dense TMZ in high-risk WHO grade 2 LGG, no PFS or OS difference in any molecular subtype.
• New 👄 Head & Neck · 2026-07-01
  ReCOG HNSCC Reirradiation Consensus
  24 of 31 (77%) statements reached ≥85% agreement: no ENI, definitive IMRT ~66 Gy, postop ~60 Gy, SBRT ~40 Gy in five fractions.
• New 🟡 Hepatobiliary · 2026-07-01
  NRG Oncology/RTOG 1112
  mOS 15.8 vs 12.3 mo with SBRT + sorafenib vs sorafenib, HR 0.77 (90% CI 0.59-1.01), not significant; mPFS HR 0.55 in locally advanced HCC.
• New 💧 Bladder · 2026-06-29 ASTRO Annual Meeting 2025
  BART
  2yr LRFFS 87.1% vs 76.0% with adjuvant pelvic RT after cystectomy, HR 0.43 (0.20-0.96), p=0.04; OS unchanged.
• New 🌰 Prostate · 2026-06-25
  ENZARAD (ANZUP 1303)
  8yr MFS 74% vs 72%, HR 0.88 (0.67-1.15), p=0.34: enzalutamide added to 2yr ADT + RT missed its primary endpoint.
• New 🌀 GI Lower · 2026-06-21
  ARS Appropriate Use Criteria: Locoregionally Recurrent Rectal Cancer
  Updated ARS appropriate use criteria for LRRC, built on 116 references (10 randomized phase 2/3), reaffirming combined-modality therapy toward R0 resection.
• New 🌰 Prostate · 2026-06-18
  PRIMARY2
  Biopsy avoided in 49%; csPCa 12% vs 16% with PSMA-PET vs systematic biopsy, non-inferior in ITT, in biopsy-naive men with equivocal or high-risk non-suspicious MRI.
• New 💧 Bladder · 2026-06-17
  INDIBLADE
  2yr bladder-intact EFS 78% (0.67-0.9) after induction ipi/nivo then chemoRT in cT2-4aN0-2 MIBC; 2yr OS 96% (0.91-1).
• New 🦴 Sarcoma · 2026-06-16
  DOREMY
  5yr LRFS 97.4% after 36Gy/18fx preop RT in myxoid liposarcoma, wound complications 21%, median f/u 66.4mo.
• New 🌰 Prostate · 2026-06-16
  REVELUTION
  Adjusted 12-mo total plaque volume rose 68.9 mm³ more with leuprolide vs relugolix in men getting prostate RT.
• New 👄 Head & Neck · 2026-06-15
  KEYNOTE-689 vs NIVOPOSTOP
  Educational round-up contrasting perioperative pembro vs postoperative nivo in resectable LA-HNSCC; 3yr DFS ~63% vs 53% cited for NIVOPOSTOP.
• New 🎀 Breast · 2026-06-14
  GEC-ESTRO Breast Cancer Working Group APBI patient selection recommendations
  Updated APBI selection criteria collapse to two groups (low-risk eligible, high-risk contraindicated), widening eligibility to pT1-2 ≤30mm, pN1mi, any histology.
• New 🌰 Prostate · 2026-06-12
  ARTO
  Adding SBRT to abiraterone in oligometastatic CRPC: biochemical response 92% vs 68.3%, OR 5.34; PFS HR 0.35.
• New 🌰 Prostate · 2026-06-12
  WOLVERINE
  IPD meta-analysis of 6 randomised phase 2 trials, 472 pts: MDT improved PFS (HR 0.44, 0.35-0.56), OS non-significant (HR 0.63, 0.39-1.00, p=0.051).
• New 🌰 Prostate · 2026-06-12
  ORIOLE
  6-mo composite progression 19% vs 61% with SABR (P=.005); mPFS not reached vs 5.8 mo, HR 0.30.
• New 🌰 Prostate · 2026-06-12
  EAU 2026: What Evidence Do We Have from Intensification with SBRT?
  Session review of MDT in oligometastatic prostate: ARTO the only randomised OS signal; no effect sizes reported in source.
• New 🌰 Prostate · 2026-06-12
  RADIOSA
  cPFS 32.2 vs 15.1 mo, HR 0.43, adding 6 months of ADT to ablative SBRT in metachronous oligorecurrence.
• New 🍽️ GI Upper · 2026-06-10
  RTOG 0848
  Adjuvant CXRT after 6 cycles gemcitabine-based chemo missed OS (HR 0.96), but node-negative pts gained: 5yr OS 48.1% vs 28.6%.
• New 🧠 CNS · 2026-06-09
  NRG Oncology RTOG 0539
  10-yr PFS 85.2% observed low-risk, 72.2% intermediate-risk at 54 Gy, 42.5% high-risk at 60 Gy.
• New 🧠 CNS · 2026-06-09
  FIRESTORM
  5-yr PFS 65.8% vs 38.8% with dose-escalated postop RT (BED ≥79.2 Gy) in high-risk meningioma; MVA HR 0.40.
• New 🎀 Breast · 2026-06-09
  RAPCHEM (BOOG 2010-03)
  10yr locoregional recurrence 2.9% (24/838) with response-adapted RT after neoadjuvant chemo; 2.4% in the RT-omission-eligible low-risk group.
• New 🌰 Prostate · 2026-06-04
  MROQC ADT Practice Patterns
  Guideline-concordant ≥18mo ADT intended in 67.0% of high-risk M0/N0-1 pts receiving definitive RT; ARPI recommended in 23.2% of STAMPEDE-eligible pts post-publication.
• New 👄 Head & Neck · 2026-06-04
  AREST
  3-yr LRFS 89.2% vs 80.9% (HR 0.52, p=0.02) with adjuvant RT vs observation in resected intermediate-risk pT1-2N0 OSCC; no significant DFS/OS difference.
• New 🌀 GI Lower · 2026-06-02 ASCO Annual Meeting 2026
  mRCAT-III
  pCR 61.0% vs 28.6% (P<0.0001) when elective nodal RT was omitted and tislelizumab added in pMMR/MSS LARC.
• New 🫁 Thoracic / Lung · 2026-06-02 ASCO Annual Meeting 2026
  LBA8005: Concurrent Thoracic RT + Chemoimmunotherapy in ES-SCLC
  mOS 10.0 vs 11.8 mo, HR 1.14 (0.84-1.56), p=0.40: adding 30Gy/10fx consolidative TRT to chemo-IO did not improve survival.
• New 🎀 Breast · 2026-06-02 ASCO Annual Meeting 2026
  RT + Systemic Therapy: What to Continue vs Hold (Speers)
  ASCO 2026 education session slides triaging concurrent systemic agents with breast/CW + RNI into continue, caution, and hold/sequence.
• New 🌀 GI Lower · 2026-06-01 ASCO Annual Meeting 2026
  ctDNA and Local Regrowth/Distant Mets in Nonoperative Rectal Cancer
  ctDNA sensitivity for local regrowth only 41% (12/29), specificity 94%; distant mets sensitivity 74%, specificity 97%.
• New 🫁 Thoracic / Lung · 2026-06-01 ASCO Annual Meeting 2026
  DeLLphi-304
  Post hoc CNS analysis: median CNS PFS NE vs 7.2mo, HR 0.54 (0.39-0.75) favoring 2L tarlatamab in SCLC.
• New 🌀 GI Lower · 2026-05-31
  MIRACLE-2
  ORR 68.0%, mOS 23.2 mo, 18% NED with HFRT/SBRT then chemo-biologic + tislelizumab in 1L MSS rectal cancer with synchronous unresectable mets.
• New 🌰 Prostate · 2026-05-31
  COMPPARE
  Bowel urgency 5.7% vs 6% (p=0.28), proton vs IMRT; no significant difference in G2+ GI toxicity or 3-yr biochemical control, localized prostate.
• New 🌰 Prostate · 2026-05-31
  PROTEUS
  No primary effect size in source; most distant mets were PSMA PET-detected (53.0% apalutamide group, 60.7% in the other group).
• New 🌰 Prostate · 2026-05-31
  CAN-2409
  DFS HR 0.70 (0.52-0.94), 2y biopsy persistence/recurrence 19.6% vs 36.4%, adding intraprostatic aglatimagene to EBRT in intermediate/high-risk localised prostate cancer.
• New 🚀 Practice-changing 🍽️ GI Upper · 2026-05-31
  RASolute 302
  Median OS 13.2 vs 6.6 mo, HR 0.40 (95% CI 0.30-0.54), P<0.001, daraxonrasib over chemo in previously treated RAS G12 metastatic pancreatic cancer.
• New 🫁 Thoracic / Lung · 2026-05-31
  OCEANUS
  Sequential RT+ICI mOS 20.3 vs 16.0 mo for concurrent, aHR 0.68 (0.47-0.99), in newly diagnosed advanced NSCLC; retrospective registry.
• New 💧 Bladder · 2026-05-30 ASCO Annual Meeting 2026
  RAD-IO
  12-mo DFS 40/50 (80%, 95% CI 0.67-0.89) with durvalumab added to 5FU/MMC chemoRT, clearing the pre-set GO bar (≥75%).
• New 💧 Bladder · 2026-05-30 ASCO Annual Meeting 2026
  Management After pCR in MIBC (Panel)
  Panel review: sandwich immunotherapy regimens continue planned adjuvant therapy regardless of pCR, with de-escalation still unanswered.
• New 💧 Bladder · 2026-05-30 ASCO Annual Meeting 2026
  Living Longer, Living Better (GU Discussant)
  ASCO 2026 GU discussant on curing more while preserving organ, bladder, and kidney function across MIBC, RCC, and ctDNA selection.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  A-DREAM
  41% treatment-free with eugonadal T at 18mo after stopping ADT+ARPI in responding mHSPC (80% CI 33.1-48.9%, one-sided p 0.0249).
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  Precision Oncology: New Biomarkers in GU Practice (Panel)
  Discussant session on biomarker readiness in prostate cancer; discordance between Decipher and clinical risk emerged in 24% of events.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  ENZAMET + Decipher
  Decipher >0.85 predicts docetaxel benefit in mHSPC on ADT+enza: HR(OS) 0.75 (0.43-1.33) vs 1.94 (0.95-3.96) if ≤0.85, interaction p=0.04.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  ARACOG (AFT-47)
  Enzalutamide MCCD decline -36.1 vs -15.8 for darolutamide at 24wks (P=0.009) in randomized phase 2, N=111.
• New 🚀 Practice-changing 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  TALAPRO-3
  3yr rPFS 77% vs 56%, stratified HR 0.48 (0.36-0.65), p<0.001, adding talazoparib to enzalutamide in HRR-deficient mCSPC.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  Clinico-transcriptomic Risk Stratification (Abstract 5000)
  ~¼ of NCCN ≥HR pts carry discordant clinical vs biomarker risk; 22-gene GC independently prognostic for MFS, DM, OS.
• New 🎀 Breast · 2026-05-30 ASCO Annual Meeting 2026
  PREPEC
  Pre-pectoral implant improved 24-mo BREAST-Q physical well-being (chest) by 4.8 points, but implant loss 21.1% vs 14.5%.
• New 🧠 CNS · 2026-05-30 ASCO Annual Meeting 2026
  ROADS
  Surgical bed recurrence 1% with GammaTile brachytherapy vs 12% post-op SRS in resected brain mets >2cm, N=230.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  CHRYSALIS-2
  Median OS 41.0 mo (95% CI 27.7-NE) with 1L amivantamab + lazertinib in atypical EGFR-mutant NSCLC, single-arm n=49.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  ESAONA
  iORR 95.5% vs 79.6% (p=0.0004) and intracranial PFS HR 0.46 favoring asandeutertinib in 1L EGFR-mutant NSCLC with brain mets.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  OptiTROP-Lung05
  mPFS NR vs 5.7mo, HR 0.35 (0.26-0.47) for sac-TMT + pembro in 1L PD-L1+ NSCLC.
• New 🍽️ GI Upper · 2026-05-30 ASCO Annual Meeting 2026
  Neo-CRAG
  Adding preop 45Gy/25fx to periop XELOX raised 3yr DFS 55.6% vs 42.4%, HR 0.750; mOS 67.5 vs 37.6mo.
• New 🤝 Supportive / QoL · 2026-05-30 ASCO Annual Meeting 2026
  SPIN Score (Celiac Plexus Radiosurgery)
  Post-hoc predictors of pain response after celiac SRS: response 32% / 53% / 89% by 0 / 1 / 2 SPIN points.
• New 🧠 CNS · 2026-05-29 ASCO Annual Meeting 2026
  Wait or Treat (NCT05236946)
  Upfront cranial RT cut intracranial progression (sub-HR 0.35, 0.21-0.59, p<0.001) but 2y OS favored delayed RT, 48% vs 60%.
• New 🚀 Practice-changing 🎀 Breast · 2026-05-27
  SENOMAC
  5yr RFS 89.7% vs 88.7% omitting completion ALND, HR 0.89 (0.66-1.19), noninferior in 1-2 SLN macromets.
• New 🫁 Thoracic / Lung · 2026-05-26
  SWOG/NRG S1914
  OS HR 1.15 (0.65-2.01), p=0.63: atezolizumab added to SBRT failed, with more local failures (13% vs 7%) and G≥3 AEs (12% vs 2%).
• New 🌐 Lymphoma · 2026-05-22
  EORTC cutaneous lymphoma RT recommendations
  Reduced-dose RT recommended across indolent cutaneous lymphomas; local MF lesions 8-12 Gy in 2-3 fx, 1-yr local control ≥92%, no randomized evidence.
• New 🎀 Breast · 2026-05-22
  DBCG IMN2
  Adjusted OS HR 0.85 (0.76-0.94) with IMNI in node-positive breast cancer; 15y OS 65.0% vs 60.8% despite taxanes, trastuzumab, AIs and 3D RT.
• New 🌰 Prostate · 2026-05-22
  PEACE V-STORM
  4yr MFS 76% vs 63% (HR 0.62, 80% CI 0.44-0.86) favoring whole-pelvis ENRT over MDT for pelvic nodal oligorecurrence, both with 6mo ADT.
• New 🎀 Breast · 2026-05-21
  SWOG S1007
  5yr LRR 0.85% with RNI vs 0.55% without after BCS+RT in RS≤25 N1 disease; IDFS unchanged by RNI.
• New 🎀 Breast · 2026-05-21
  EORTC 22922/10925
  20yr OS 61.0% vs 61.8% (HR 1.00, p=.967): IM-MS nodal RT cut breast cancer mortality but added non-cancer deaths.
• New 💧 Bladder · 2026-05-21
  Bladder Adjuvant Radiotherapy
  2yr LRFS 87.1% vs 76.0% with adjuvant pelvic IMRT after RC, HR 0.43 (0.20-0.96), P=.04; DFS/BCSS/OS not significant.
• New 🎀 Breast · 2026-05-20
  Pencil beam scanning proton vs IMRT photon PMRT: capsular contracture risk
  Proton vs photon PMRT CC HR 1.76 (0.93-3.32, P=.083) on MVA; 2-yr CC 50% with protons plus DTI.
• New 🎀 Breast · 2026-05-20
  NRG/RTOG 9804 + E5194 combined analysis (tamoxifen after lumpectomy, DCIS)
  15-yr IBR 11.4% vs 19.0% with vs without tamoxifen in good-risk DCIS treated by lumpectomy without RT; invasive IBR HR 0.43.
• New 🫁 Thoracic / Lung · 2026-05-20
  High-dose hyperfractionated SIB RT vs standard-dose RT for limited-stage SCLC
  mOS 60.7 vs 39.5 mo, HR 0.55 (0.37–0.72), p=0.003 with 54 Gy/30 fx BID SIB vs 45 Gy/30 fx BID in LS-SCLC; toxicity similar.
• New 🌰 Prostate · 2026-05-19 ESTRO Congress 2026
  ePLND vs PSMA-PET staging (AUA2026 round-up)
  AUA2026 round-up: PSMA-PET NPV ~96% may allow PLND omission in intermediate risk; 47.7% of nodal mets sit outside ePLND template.
• New 💧 Bladder · 2026-05-19 ESTRO Congress 2026
  Bladder-preserving TMT multicenter analysis (URONCOR)
  CLR 63.7% in a 369-pt Spanish TMT cohort; salvage cystectomy 9.7%, image-guidance quality and 5-FU-based CRT predicted local response.
• New 🫁 Thoracic / Lung · 2026-05-19 ESTRO Congress 2026
  Single-fraction SABR pooled analysis, 1687 pts
  Local control 90-93% at 2yr and G3+ AEs 2.9% across 1687 single-fraction SABR pts at 3 centres.
• New 🌀 GI Lower · 2026-05-18 ESTRO Congress 2026
  OPERA
  W14 clinical response (DRE+rectoscopy) identified 76% good responders; 5yr organ preservation 75% A vs 83% B, p=0.24.
• New 🌰 Prostate · 2026-05-18 ESTRO Congress 2026
  HEAT
  Interim: BF 7% vs 7.4% at 4.25y, p-non-inferiority 0.007, 5-fx SBRT non-inferior to 26-fx IMRT with ADT allowed.
• New 👄 Head & Neck · 2026-05-18 ESTRO Congress 2026
  INRT-AIR & DARTBOARD pooled analysis
  5yr solitary elective nodal recurrence 0% with ENI omission in HNSCC; 5yr OS 87%, PFS 74%, n=117.
• New 🚀 Practice-changing 🎀 Breast · 2026-05-18 ESTRO Congress 2026
  NRG/RTOG 1005
  7yr IBR 2.6% concurrent vs 2.2% sequential, HR 1.31 (90% CI 0.84-2.04), noninferior, one shorter course.
• New 🟡 Hepatobiliary · 2026-05-18 ESTRO Congress 2026
  Multinational HCC EBRT IPD Cohort
  Median OS 6.8y BCLC-0 and 4.6y BCLC-A across 4,913 EBRT-treated HCC pts, comparable to resection and ablation.
• New 🎯 Oligometastatic / Mets · 2026-05-18 ESTRO Congress 2026
  EXTEND
  PFS HR 0.54 (0.41-0.72), p<0.001 for MDT added to SOC across 6 oligometastatic baskets; RT delivered 98% of MDT.
• New 🫘 Kidney · 2026-05-18 ESTRO Congress 2026
  FASTRACK II
  100% freedom from local progression at 36, 60, and 84mo after single-fraction 26Gy or 42Gy/3fx SABR in inoperable primary RCC.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  POP-RT vs PEACE-2
  WPRT bFFS HR 0.50 (POP-RT) vs bPFS HR 0.97 (PEACE-2); pelvic RT benefit vanishes with 3yr ADT, PSMA staging.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PRIME
  Interim: acute grade ≥2 GU ~5.4% vs ~4.0% (p=0.59) for 5-fx SBRT vs 25-fx, both with whole-pelvis RT; BFFS immature.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PIVOTALboost
  Adding pelvic nodal IMRT to a focal prostate boost in 20fx raised early bowel toxicity only; 2yr G2+ rates similar across arms.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PACE-NODES
  CTCAE G2+ GI toxicity 28% vs 21% with added pelvic nodal SBRT; no GU difference, symptoms resolved by 12wk.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PEACE-2
  cPFS HR 0.81 (0.63-1.03), p=0.088: pelvic RT over prostate-only missed its primary endpoint in very-high-risk N0M0.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  OLIGOMA
  mPFS 35.8 vs 20.4mo, HR 0.48 (0.25-0.91) p=0.021 with ablative RT to all lesions in oligometastatic breast.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  APBI-IMRT Florence
  15-yr IBTR 7.7% APBI vs 4.2% WBI, HR 1.57 (0.82-3.04) p=0.17; excess driven by new ipsilateral primaries, not true local relapse.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  EORTC IM-MS (22922/10925)
  20yr OS 61.0% vs 61.8%, HR 1.00 (0.90-1.10), P=0.967: the 15yr breast-cancer mortality benefit is erased by non-BCM.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  DBCG RT Natural
  5yr invasive LR 1.5% with PBI vs 9.8% randomised no-PBI vs 8.2% self-selected no-PBI at 4yr median f/u.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  IMPORT HIGH
  10yr IBTR 3.7% with 48Gy/15F SIB vs 3.5% with 40Gy/15F + 16Gy/8F sequential; 53Gy/15F higher at 5.5%.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  DBCG HYPO
  10yr grade 2-3 breast induration 24.7% (50Gy) vs 19.5% (40Gy), HR 0.76 (0.62-0.92), p=0.005, no recurrence penalty.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  HypoG-01
  118 first events over 4.8yr median f/u; 67% of LRR sites in-volume, patterns comparable across 40Gy/15fx and 50Gy/25fx.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  Tumour bed boost after BCS+WBRT (Dutch cohort)
  10yr IBTR 1.2% with 0-2 risk factors regardless of boost, supporting boost omission in the modern systemic era.
• New 🎯 Oligometastatic / Mets · 2026-05-17 ESTRO Congress 2026
  OligoCare
  Real-world SABR local failure 5.0% at 1yr, 11.4% at 3yr across 2447 pts / 3533 lesions; CRC worst at 19.6%.
• New 🫘 Kidney · 2026-05-17 ESTRO Congress 2026
  RCC SBRT (5-year local control)
  100% local control at 5 years for RCC treated with SBRT, per a conference slide; no N, dose, or CI in source.
• New 👄 Head & Neck · 2026-05-17 ESTRO Congress 2026
  DIREKHT
  De-escalated post-op HNSCC RT: contralateral neck sparing and primary CTV to 56 Gy in selected pts; no outcome numbers in source tweet.